Perceptive Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-750,000
Closed -$2.65M – 113
2022
Q3
$2.65M Buy
+750,000
New +$2.48M 0.08% 96
2021
Q4
– Sell
-787,745
Closed -$5.74M – 159
2021
Q3
$5.74M Hold
787,745
– – 0.08% 118
2021
Q2
$7.89M Hold
787,745
– – 0.1% 115
2021
Q1
$7.52M Hold
787,745
– – 0.1% 103
2020
Q4
$8.64M Hold
787,745
– – 0.09% 110
2020
Q3
$6.99M Buy
+787,745
New +$8.96M 0.1% 100

Other funds holding PSTX

Perceptive Advisors's PSTX Position: Q4 2022 in Review

Perceptive Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2022, closing a stake of 750,000 shares — an estimated $2.65M sold.

Perceptive Advisors first reported a position in PSTX in Q3 2020 and held it in 6 quarters. The position peaked at $8.64M in Q4 2020. 89 funds tracked by Wall St. Rank hold PSTX as of Q4 2022.

  • Perceptive Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Perceptive Advisors sold 750,000 Poseida Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $2.65M.
  • Perceptive Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
  • Perceptive Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $8.64M in Q4 2020.
  • 89 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.